Published in J Natl Med Assoc on July 01, 1986
DNA methylation and gene function. Science (1980) 14.01
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med (1982) 3.29
Marrow transplantation for thalassaemia. Lancet (1982) 1.71
5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood (1983) 1.61
Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci U S A (1983) 1.60
Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med (1984) 1.54
Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5-azacytidine. Blood (1984) 1.33
Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med (1984) 1.32
Mechanical properties of oxygenated red blood cells in sickle cell (HbSS) disease. Blood (1984) 1.04
Hb F synthesis in sickle cell anaemia: a comparison of Saudi Arab cases with those of African origin. Br J Haematol (1980) 0.96
Marrow transplantation for nonmalignant disorders. N Engl J Med (1985) 0.83
The irreversibly sickled cell. Am J Pediatr Hematol Oncol (1982) 0.81
Neuropsychological status at seizure onset in children: risk factors for early cognitive deficits. Neurology (2009) 2.46
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst (1994) 2.05
Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol (2004) 1.70
Transient stress lymphocytosis during crisis of sickle cell anemia and emergency trauma and medical conditions. An immunophenotyping study. Arch Pathol Lab Med (1990) 1.39
Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res (2001) 1.35
Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood (1991) 1.35
1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res (1999) 1.27
Behavior problems in children at time of first recognized seizure and changes over the following 3 years. Epilepsy Behav (2011) 1.27
Photon correlation spectroscopy of hemoglobin: diffusion of oxy-HbA and oxy-HbS. Biopolymers (1978) 1.25
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology (1997) 1.24
Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res (1997) 1.20
Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol (1997) 1.20
Formation and alignment of Z lines in living chick myotubes microinjected with rhodamine-labeled alpha-actinin. J Cell Biol (1986) 1.19
Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem (2001) 1.19
Modulation of angiotensin II-induced vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole. J Clin Invest (1991) 1.15
A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res (1999) 1.12
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res (2000) 1.11
Pregelation aggregation of sickle cell hemoglobin. Proc Natl Acad Sci U S A (1974) 1.11
Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res (2001) 1.09
Myocardial infarction in sickle cell disease. J Natl Med Assoc (1996) 1.08
Sickle cell anemia: does myocardial ischemia occur during crisis? J Natl Med Assoc (1991) 1.07
Mechanical properties of oxygenated red blood cells in sickle cell (HbSS) disease. Blood (1984) 1.04
Pathological spectrum of liver diseases in sickle cell disease. Dig Dis Sci (1986) 1.03
Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. Am J Clin Nutr (1997) 1.03
Perceived social support among depressed elderly, middle-aged, and young-adult samples: cross-sectional and longitudinal analyses. J Affect Disord (1999) 1.02
Liver involvement in sickle cell disease. Medicine (Baltimore) (1985) 1.00
Bone regeneration within a human segmental mandible defect: a preliminary report. Am J Otolaryngol (1995) 1.00
A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg (1997) 0.98
Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol (2001) 0.98
Identification of eleven human hemoglobin variants by high-performance liquid chromatography: additional data on functional properties and clinical expression. Biochem Genet (1982) 0.98
Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst (1998) 0.97
Arterial blood pressure in adults with sickle cell disease. Arch Intern Med (1981) 0.97
Effect of polymerization tendency on haematological, rheological and clinical parameters in sickle cell anaemia. Br J Haematol (1989) 0.96
Academic problems in children with seizures: relationships with neuropsychological functioning and family variables during the 3 years after onset. Epilepsy Behav (2010) 0.96
A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol (2000) 0.95
Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors. Cancer Res (1988) 0.94
Catalysis of the disproportionation of superoxide by metalloporphyrins. III. J Inorg Biochem (1981) 0.94
Racial patterns in pernicious anemia. Early age at onset and increased frequency of intrinsic-factor antibody in black women. N Engl J Med (1978) 0.93
Effects of Host Resistance and Temperature on Development of Globodera tabacum solanacearum. J Nematol (2001) 0.93
Age and growth factors in porcine full-thickness wound healing. Wound Repair Regen (2002) 0.93
Lecithin inverse microemulsions for the pulmonary delivery of polar compounds utilizing dimethylether and propane as propellants. Pharm Dev Technol (2000) 0.93
Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res (1994) 0.92
Endothelium-derived relaxing factor modulates endothelin action in afferent arterioles. Hypertension (1991) 0.92
Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease. Clin Sci (Lond) (1989) 0.92
Rheology of the sickle cell disorders. Baillieres Clin Haematol (1987) 0.91
Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol (1996) 0.90
Managing Root-knot on Tobacco in the Southeastern United States. J Nematol (1989) 0.90
Influence of oxygen tension on the viscoelastic behavior of red blood cells in sickle cell disease. Blood (1986) 0.90
Unsuspected pernicious anemia in a patient with sickle cell disease receiving routine folate supplementation. Arch Intern Med (1987) 0.88
Electrocardiogram analysis in adult patients with sickle cell disease. J Natl Med Assoc (1987) 0.88
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol (2011) 0.88
Relation between absolute thresholdand duration-of-tone pulses in the bottlenosed porpoise. J Acoust Soc Am (1968) 0.88
alpha-Thalassemia: prevalence and hematologic findings in American Blacks. Arch Intern Med (1982) 0.87
Rheologic impairment of sickle RBCs induced by repetitive cycles of deoxygenation-reoxygenation. Blood (1988) 0.87
Induction of leukemia regression in mice by immunotherapeutic transfer of T-lymphocytes. Cancer Res (1986) 0.86
Familial sarcoidosis. Report of four siblings with acute sarcoidosis. Am Rev Respir Dis (1971) 0.85
Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res (1996) 0.85
Interleukin-1 alpha-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents. Int J Radiat Biol (1991) 0.84
Pernicious anemia in Latin Americans is not a disease of the elderly. Arch Intern Med (1987) 0.84
The effect of fetal hemoglobin on the sickling dynamics of SS erythrocytes. Blood Cells (1983) 0.84
Masked tonal thresholds in the bottlenosed porpoise. J Acoust Soc Am (1968) 0.83
Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Investig (2000) 0.83
Blood transfusions and immunophenotypic alterations of lymphocyte subsets in sickle cell anemia. The Transfusion Safety Study Group. Blood (1995) 0.83
Diagnosis and treatment of patients with gastroesophageal reflux and noncardiac chest pain. South Med J (1994) 0.82
Tracer diffusion coefficients of oxyhemoglobin A and oxyhemoglobin S in blood cells as determined by pulsed field gradient NMR. Biophys Chem (1982) 0.82
31P-nuclear magnetic resonance studies of the effect of recombinant human interleukin 1 alpha on the bioenergetics of RIF-1 tumors. Cancer Res (1989) 0.82
Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol (1997) 0.82
Prostatic asymmetry as a risk factor for prostatic carcinoma: serial prostate-specific antigen monitoring and cancer detection. Br J Urol (1997) 0.82
Tracheoesophageal speech: predictors of success and social validity ratings. Am J Otolaryngol (1998) 0.81
Iron deficiency occurs frequently in patients with pernicious anemia. JAMA (1987) 0.81
Vitamin D in the prevention and treatment of prostate cancer. Semin Urol Oncol (1999) 0.81
The first example of a deletion in the human alpha chain: hemoglobin Boyle Heights or alpha 2 6 (A4) Asp----to O beta 2. Hemoglobin (1983) 0.80
Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope (1998) 0.80
Elastic properties of deoxy hemoglobin S (deoxy-HbS) gels. Arch Biochem Biophys (1981) 0.80
Correlates of suicidal ideation among an elderly depressed sample. J Affect Disord (1999) 0.80
Intraspecific Variability within Globodera tabacum solanacearum Using Random Amplified Polymorphic DNA. J Nematol (2004) 0.79
Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Semin Oncol (1996) 0.79
Inhibition of normal erythropoiesis in mice with Friend virus induced erythroleukemia. Exp Hematol (1982) 0.79
Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol (1996) 0.78
Transport of probe molecules through fibrin gels as observed by means of holographic relaxation methods. Biopolymers (1988) 0.78
Priapism. Hematol Oncol Clin North Am (1996) 0.78
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol (2013) 0.78
Profiles of black and Latin-American patients having pernicious anemia. HLA antigens, lymphocytotoxic antibody, anti-parietal cell antibody serum gastrin levels, and ABO blood groups. Am J Clin Pathol (1981) 0.78
Racial differences in serum total bilirubin levels in health and in disease (pernicious anemia). JAMA (1985) 0.78
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer (1997) 0.78
Mechanism of macrophage reversal of Friend erythroleukemia: macrophage regulation of normal and leukemic erythropoiesis. Cancer Res (1986) 0.78
Thalassemia minor: routine erythrocyte measurements and differentiation from iron deficiency. Am J Clin Pathol (1983) 0.77
Programmed cell death in extraocular muscle tendon/sclera precursors. Mol Vis (2001) 0.77
Landmark perspective. Sickle cell anemia. JAMA (1985) 0.77
Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res (1994) 0.77
Potentiation of interleukin 1 alpha mediated antitumor effects by ketoconazole. Cancer Res (1990) 0.77
Simultaneous measurement of vesicle diffusion coefficients and trapping efficiencies by means of diffusion ordered 2D NMR spectroscopy. Chem Phys Lipids (1994) 0.77
Pedicled osseous flaps. Otolaryngol Clin North Am (1994) 0.76
Efficacy of dart or booster vaccination with strain RB51 in protecting bison against experimental Brucella abortus challenge. Clin Vaccine Immunol (2012) 0.76
Hemoglobin Pasadena,alpha 2 beta 275(E19)Leu leads to Arg. Identification by high performance liquid chromatography of a new unstable variant with increased oxygen affinity. Biochim Biophys Acta (1980) 0.76
Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Vet Comp Oncol (2010) 0.76
Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha. Cancer Res (1991) 0.76
Tracer diffusion coefficients of proteins by means of holographic relaxation spectroscopy: application to bovine serum albumin. Anal Biochem (1985) 0.76
Osteopontin immunoreactivity in the ileum and ileocecal lymph node of dairy cows naturally infected with Mycobacterium avium subsp. paratuberculosis. Vet Immunol Immunopathol (2008) 0.76